Abeona Therapeutics Inc
ABEO
Company Profile
Business description
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Contact
6555 Carnegie Avenue
4th Floor
ClevelandOH44103
USAT: +1 646 813-4701
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
136
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.40 | 25.00 | -0.28% |
| CAC 40 | 7,850.43 | 106.02 | 1.37% |
| DAX 40 | 24,240.82 | 198.92 | 0.83% |
| Dow JONES (US) | 45,010.29 | 507.85 | 1.14% |
| FTSE 100 | 9,061.49 | 37.68 | 0.42% |
| HKSE | 25,688.87 | 150.80 | 0.59% |
| NASDAQ | 21,020.02 | 127.33 | 0.61% |
| Nikkei 225 | 41,866.16 | 694.84 | 1.69% |
| NZX 50 Index | 12,808.84 | 14.78 | 0.12% |
| S&P 500 | 6,358.91 | 49.29 | 0.78% |
| S&P/ASX 200 | 8,707.10 | 30.10 | -0.34% |
| SSE Composite Index | 3,599.44 | 17.14 | 0.48% |